O	0	1	A
O	2	7	phase
O	8	10	II
O	11	21	randomized
O	22	27	study
O	28	30	of
O	31	34	two
B-intervention	35	42	taxanes
I-intervention	43	46	and
I-intervention	47	56	cisplatin
O	57	60	for
O	61	71	metastatic
O	72	78	breast
O	79	85	cancer
O	86	91	after
O	92	105	anthracycline
O	105	106	:
O	107	108	a
O	109	114	final
O	115	123	analysis
O	123	124	.

O	125	128	The
O	129	136	purpose
O	137	139	of
O	140	143	the
O	144	149	study
O	150	152	is
O	153	155	to
O	156	163	compare
O	164	167	two
O	168	175	taxanes
O	175	176	/
O	176	185	cisplatin
O	186	198	combinations
O	199	202	for
O	203	213	metastatic
O	214	220	breast
O	221	227	cancer
O	228	230	in
O	231	236	terms
O	237	239	of
O	240	244	time
O	245	247	to
O	248	255	disease
O	256	267	progression
O	267	268	,
O	269	277	response
O	278	283	rates
O	284	287	and
O	288	296	toxicity
O	296	297	.

O	298	305	Between
O	306	311	April
O	312	316	2000
O	317	320	and
O	321	329	December
O	330	334	2002
O	334	335	,
B-total-participants	336	339	101
B-eligibility	340	348	patients
I-eligibility	349	353	with
I-eligibility	354	362	advanced
I-eligibility	363	369	breast
I-eligibility	370	379	carcinoma
I-eligibility	379	380	,
I-eligibility	381	391	previously
I-eligibility	392	399	treated
I-eligibility	400	404	with
I-eligibility	405	407	an
I-eligibility	408	421	anthracycline
I-eligibility	422	425	but
I-eligibility	426	429	not
I-eligibility	430	434	with
I-eligibility	435	436	a
I-eligibility	437	443	taxane
O	443	444	,
O	445	449	were
O	450	458	enrolled
O	458	459	.

B-intervention-participants	460	465	Fifty
O	466	474	patients
O	475	479	were
O	480	487	treated
O	488	492	with
O	493	502	docetaxel
O	503	505	60
O	506	508	mg
O	508	509	/
O	509	511	m2
O	512	515	and
O	516	525	cisplatin
O	526	528	50
O	529	531	mg
O	531	532	/
O	532	534	m2
O	534	535	,
O	536	539	and
B-control-participants	540	542	51
O	543	551	patients
O	552	556	were
O	557	564	treated
O	565	569	with
B-control	570	580	paclitaxel
I-control	581	584	175
I-control	585	587	mg
I-control	587	588	/
I-control	588	590	m2
I-control	591	594	and
I-control	595	604	cisplatin
I-control	605	607	50
I-control	608	610	mg
I-control	610	611	/
I-control	611	613	m2
O	613	614	.

O	615	619	Each
O	620	625	cycle
O	626	634	repeated
O	635	640	every
O	641	642	3
O	643	648	weeks
O	648	649	.

O	650	653	The
B-outcome	654	661	overall
I-outcome	662	670	response
I-outcome	671	675	rate
O	676	679	was
B-iv-bin-percent	680	682	62
I-iv-bin-percent	682	683	.
I-iv-bin-percent	683	684	5
O	685	688	and
B-cv-bin-percent	689	691	42
I-cv-bin-percent	691	692	.
I-cv-bin-percent	692	693	6
I-cv-bin-percent	693	694	%
O	695	697	in
O	698	701	the
O	702	711	docetaxel
O	712	715	and
O	716	726	palcitaxel
O	727	733	groups
O	734	746	respectively
O	747	748	(
O	748	749	P
O	750	751	=
O	752	753	0
O	753	754	.
O	754	756	06
O	756	757	)
O	757	758	.

B-outcome	759	765	Median
I-outcome	766	770	time
I-outcome	771	773	to
I-outcome	774	781	disease
I-outcome	782	793	progression
O	794	797	was
B-iv-cont-median	798	799	9
I-iv-cont-median	799	800	.
I-iv-cont-median	800	801	8
O	802	805	and
B-cv-cont-median	806	807	6
I-cv-cont-median	807	808	.
I-cv-cont-median	808	809	5
I-cv-cont-median	810	816	months
O	817	819	in
O	820	829	docetaxel
O	830	833	and
O	834	844	paclitaxel
O	845	851	groups
O	852	864	respectively
O	865	866	(
O	866	867	P
O	868	869	=
O	870	871	0
O	871	872	.
O	872	874	15
O	874	875	)
O	875	876	.

O	877	880	The
B-outcome	881	887	median
I-outcome	888	895	overall
I-outcome	896	904	survival
I-outcome	905	909	time
O	910	913	was
B-iv-cont-median	914	916	22
I-iv-cont-median	916	917	.
I-iv-cont-median	917	918	7
I-iv-cont-median	919	925	months
O	926	928	in
O	929	932	the
O	933	942	docetaxel
O	943	946	arm
O	947	950	and
B-cv-cont-median	951	953	22
I-cv-cont-median	953	954	.
I-cv-cont-median	954	955	4
I-cv-cont-median	956	962	months
O	963	965	in
O	966	969	the
O	970	980	paclitaxel
O	981	984	arm
O	984	985	.

B-outcome	986	991	Grade
I-outcome	992	993	3
I-outcome	993	994	/
I-outcome	994	995	4
I-outcome	996	1006	arthralgia
I-outcome	1006	1007	/
I-outcome	1007	1014	myalgia
O	1014	1015	,
B-outcome	1016	1023	sensory
I-outcome	1024	1034	neuropathy
O	1035	1038	and
B-outcome	1039	1045	anemia
O	1046	1054	occurred
O	1055	1059	more
O	1060	1070	frequently
O	1071	1073	in
O	1074	1077	the
O	1078	1088	paclitaxel
O	1089	1092	arm
O	1092	1093	,
O	1094	1099	while
O	1100	1104	more
B-outcome	1105	1114	mucositis
O	1114	1115	,
B-outcome	1116	1123	fatigue
O	1124	1127	and
B-outcome	1128	1139	neutropenia
O	1140	1148	occurred
O	1149	1151	in
O	1152	1155	the
O	1156	1165	docetaxel
O	1166	1169	arm
O	1169	1170	.

O	1171	1177	Taxane
O	1177	1178	/
O	1178	1187	cisplatin
O	1188	1200	combinations
O	1201	1205	were
O	1206	1212	active
O	1213	1216	for
O	1217	1225	advanced
O	1226	1232	breast
O	1233	1239	cancer
O	1239	1240	,
O	1241	1246	while
O	1247	1252	there
O	1253	1261	appeared
O	1262	1264	to
O	1265	1267	be
O	1268	1276	evidence
O	1277	1279	in
O	1280	1285	favor
O	1286	1288	of
O	1289	1290	a
O	1291	1300	docetaxel
O	1300	1301	/
O	1301	1310	cisplatin
O	1311	1322	combination
O	1322	1323	.

O	1324	1327	The
O	1328	1336	toxicity
O	1337	1339	in
O	1340	1345	favor
O	1346	1348	of
O	1349	1358	docetaxel
O	1358	1359	/
O	1359	1368	cisplatin
O	1369	1377	warrants
O	1378	1384	future
O	1385	1390	first
O	1390	1391	-
O	1391	1395	line
O	1396	1404	clinical
O	1405	1411	trials
O	1411	1412	.
